Data supporting the routine use of PhasED-Seq® for MRD analysis in DLBCL featured in Precision Oncology News
Aurora, Colo. December 15, 2022—Precision Oncology News featured compelling evidence presented at the 2022 American Society for Hematology meeting that supports the routine use of Foresight Diagnostics’ PhasED-Seq platform for the detection of circulating tumor DNA (ctDNA) in patients with diffuse large B-cell lymphomas (DLBCL) and as a surrogate endpoint for future clinical studies.
Dr. Mark Roschewski, clinical director of the National Cancer Institute’s Lymphoid Malignancies Branch, presented pooled data from 5 clinical trials, each evaluating a different chemotherapy combination, that demonstrated the prognostic significance of PhasED-Seq to determine progression-free survival following treatment. In each of the clinical studies, the PhasED-Seq assay was used to analyze tumor or plasma and peripheral blood monocytes (PBMCs) from patients before, during, and after treatment. The ability of PhasED-Seq to detect ctDNA, particularly at the end of treatment, was highly predictive of disease progression when compared to patients without detectable levels.
PhasED-Seq also showed greater sensitivity for detection of minimal residual disease (MRD) as compared to standard PET and CT imaging, enabling the identification of patients at risk for relapse that may otherwise have been considered cured. PhasED-Seq could improve current response criteria and serve as a promising alternative clinical trial endpoint.
The Precision Oncology News release, with detailed information on the data presented, can be found here.
Back to all